Is a new 'PGD2' hair loss cure imminent?

Reports have started circulating regarding a potential new hair loss “cure”, which could be available in as little as two years -so, potentially by the summer of 2014. This new treatment is built upon existing research regarding male pattern baldness, and an enzyme called prostaglandin D2 (PGD2).

The discovery of PGD2’s role in hair loss has been documented for some time, but according to reports a new agreement between scientists and drug companies could see a potential treatment available for use by men and women within two years.

Chemical Structure of PGD2 Prostaglandin D2A team of scientists working at the University of Pennsylvania have discovered PGD2 plays a significant role in genetic hair loss, and that certain drugs commonly used to treat asthma and allergies - including setipiprant - inhibit its action on hair. Discussions are underway to arrange full-scale trials of these medications as potential hair loss treatment.

Two years is a long time to wait

Despite the excitement surrounding these new developments, it is worth noting that Dr Cotsarelis, who heads up the University research team, is still only in early negotiations with pharmaceutical manufacturers. There is also a heavy emphasis on the word “could” when discussing the two year timescale to launch, suggesting it could be considerably longer before this new hair loss treatment is made widely available.

Worth believing the hype?

It seems every 6 months or so a front-page story is published detailing a potential revolutionary cure for baldness. Below are four similar stories from the past 18 months, proving such stories shouldn't be taken so seriously, especially since there are already a number of treatments available that are extremely effective in preventing hair loss and regrowing hair and at this time there is no strong evidence to indicate that these potential treatments would be any better.

Scientists find new hair loss clue

Scientists believe 'werewolf gene' may unlock future baldness cure

Acell and prp combination revolutionary hairloss cure

Accidental cure for baldness astressin-b indicates hair growth properties

Treating hair loss now

Although PGD2 inhibitors are an exciting development, there are already medically proven treatments available which slow hair loss and promote regrowth.

As a consequence, there is no reason why any man or woman experiencing hairloss need delay treatment in advance of the release of Dr Cotsarelis’ new drug. In fact, Belgravia specialists' experience suggests that the sooner people experiencing pattern balding begin treatment, the better.

No more uncertainty

Despite the findings at the University of Pennsylvania, Dr Cotsarelis remains remarkably reserved about the potential of his PGD2 blocker as a true hair loss treatment. “We certainly think it would be good at preventing hair loss,” Cotsarelis said in an interview with the Daily Mail, “but we don’t know for sure that it would regrow.”

As Male Pattern Baldness is a permanent and progressive hair loss condition, once signs start showing, for those who want to take proactive action towards preventing baldness, it is wise to seek professional advice about suitable hair loss solutions as early as possible. 

That way, even if new treatments or therapies become available in the future - medications generally take a number of years to develop and receive the necessary medical regulatory authorisations - at least you'll be on top of managing your condition without having to worry about it in the meantime.

Copy of New Street Ground Floor Reception 1 no pink nail polish

The Belgravia Centre

The Belgravia Centre is a world-renowned group of a hair loss clinic in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation from anywhere in the world for home-use treatment.

View our Hair Loss Success Stories, which includes the world's largest gallery of hair growth photos and demonstrates the level of success that so many of Belgravia's patients achieve.